Ofatumumab (Arzerra®) (Refractory CLL)

Assessment Status Rapid Review Complete
Drug Ofatumumab
Brand Arzerra®
Indication For the treatment of CLL in patients who are refractory to fludarabine and alemtuzumab.
Assessment Process
Rapid review commissioned 01/06/2010
Rapid review completed 22/06/2010
Rapid review outcome Full Pharmacoeconomic Assessment Recommended

The company has not submitted a HTA dossier to the NCPE therefore the cost effectiveness of the technology could not be proven.